Company profile for MEDIPOST Co., Ltd

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Since its foundation, the company has stayed on the right course in the midst of countless adversities in stem cell industry and through years of cutting-edge research, MEDIPOST has taken a dominating step in the global biomedical field by achieving market approval of the world’s first allogeneic stem cell drug – CARTISTEM®, in Korea. Biotechnology is believed to be one of the leading industries which will provide a spri...
Since its foundation, the company has stayed on the right course in the midst of countless adversities in stem cell industry and through years of cutting-edge research, MEDIPOST has taken a dominating step in the global biomedical field by achieving market approval of the world’s first allogeneic stem cell drug – CARTISTEM®, in Korea. Biotechnology is believed to be one of the leading industries which will provide a springboard for korea’s future economic growth. We at MEDIPOST, will continue to do our very best to overcome the current limitations of the treatment paradigm for incurable diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
644 beon-gil 21, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do
Telephone
Telephone
+82 2-3465-6677
Linkedin
Linkedin
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/medipost-announces-the-exclusive-commercialization-license-agreement-with-teikoku-seiyaku-for-knee-osteoarthritis-treatment-cartistem-in-japan-302646492.html

PR NEWSWIRE
19 Dec 2025

https://www.businesswire.com/news/home/20241202720121/en

BUSINESSWIRE
03 Dec 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty